John M. Kane

TL;DR: The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation in schizophrenia.

TL;DR: An expert advisory subgroup of the Treatment Response and Resistance in Psychosis working group developed the following background, recommendations and rationale as a consensus statement: clozapine prescribing guidance and facilitate regulatory agencies modifying laboratory monitoring and/or dispensing requirements.

TL;DR: Hyperthermia malignant Delirium NMS Depressed level of consciousness Serotonin syndrome Disorientation Body temperature increased Extrapyramidal disorder Hyperpyrexia Heart rate abnormal Pyrexia heart rate increased Catatonia Hyperhidrosis Dyskinesia Hypertension Dystonia Hypotension Freezing phenomenon Labile blood pressure Hyperkinesias Labile hypertension Hypertonia Leukocytosis Muscle necrosis Loss of consciousness Muscle rigidity Muscle enzyme increased

TL;DR: The authors and journal are complimented for ensuring the “Consensus statement on the use of clozapine during the COVID-19 pandemic” was published in a timely fashion.

TL;DR: Not only overweight but also obesity is protective, which has relevant nutritional goal implications in this population/setting, and RR results corroborated primary HR results, with additionally lower infection-related mortality in overweight and obese than in normal-weight indi- viduals.